Massive study pits tirzepatide against semaglutide in heart failure showdown
NCT ID NCT06914141
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study looked at over 28,000 people with type 2 diabetes and a specific type of heart failure (HFpEF) to compare two drugs: tirzepatide and semaglutide. The goal was to see which one better prevents death or hospitalization due to heart failure. The research used existing medical records to mimic a head-to-head trial, aiming to provide real-world evidence on which treatment is more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.